Table 1.
General characteristics of PI3K pan-inhibitors in mouse models.
| Author | Publication year | Model | Fluid or blood | N Exp | N Con | Drug | Dose | Primary outcomes |
|---|---|---|---|---|---|---|---|---|
| Campa11 | 2018 | OVA induced C57BL/6J and BALB/c mice | BALF | 10 | 6 | CL27c | 2 mg/mL | E, N, L, M, T, 5, 13 |
| Wagh12 | 2017 | OVA induced BALB/c mice | BALF | 6 | 6 | INK654 | 30 mg/kg | E, N, L, M, T, α, 2, 5, 6, γ |
| Huang13 | 2017 | IL-25 induced BALB/c mice | BALF | 5 | 5 | LY294002 | 80 μg/50 μL | E, N, L, T, α, 5, 6, 13, Eo, 1β, β, V |
| Oikawa14 | 2016 | OVA induced C57BL6 mice | BALF (cytokines), blood (cell counts) | 6 | 6 | ZSTK474 | 30 mg/kg | E, T, 4, 5, 13, β |
| Saw15 | 2016 | Cockroach induced BALB/c mice | BALF (cell counts, cytokines), blood (I) | 6 | 6 | LY294002 | 3 mg/kg | E, N, T, 4, 5, 13, 10, 12, I |
| Yao16 | 2015 | TDI induced BALB/c mice | BALF (cell counts), blood (I) | 8 | 8 | LY294002 | 1.5 mg/kg | E, N, L, M, T, I |
| Liang17 | 2015 | TDI induced BALB/c mice | BALF (cell counts,4), blood (I) | 7 | 7 | LY294002 | 1.5 mg/kg | E, N, L, M, T, I, 4 |
| Choi18 | 2013 | OVA induced BALB/c mice | BALF | 5 | 5 | LY294002 | 1.5 mg/kg | E, N, L, M, T, 4, 5, 13, α, 1β, Eo |
| Xia19 | 2012 | OVA induced rat | BALF | 8 | 8 | Wortmannin | 15 μg/kg | E, N, L, M, 4, γ |
| Duan20 | 2005 | OVA induced BALB/c mice | BALF | 6 | 6 | LY294002 | 3.75 mg/kg | E, N, L, M, T, 4, 5, 13, Eo, γ |
| Kwak21 | 2003 | OVA induced BALB/c mice | BALF | 6 | 6 | Wortmannin | 100 μg/kg | E, N, L, M, T, 4, 5 |
Abbreviations: Exp: experimental; Con: control; BALF: bronchoalveolar lavage fluid; OVA: ovalbumin; TDI: toluene diisocyanate; E: eosinophils; N: neutrophils; L: lymphocytes; M: macrophages; T: total cell counts; I: IgE; α: TNF-α; 2: IL-2; 4: IL-4; 5: IL-5; 6: IL-6; 10: IL-10; 12: IL-12; 13: IL-13; γ: IFN-γ; β: TGF-β; 1β: IL-1β; Eo: eotaxin; V, VEGF.